2026 Q2 -tulosraportti
Tänään
‧40 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·10 t sitten · Muokattu".. the extensive amount of new clinical data we expect to release .." Found these positive lines from the report on the second half of 2026. When they release it, it can probably help the stock price a bit. Provided that everything goes as they hope: "A second catalyst will be the ASSURE registry, a real-world study of the PancreaSure test’s use and impact. The study has generated significant interest among pancreatic cancer experts, who see the study as a way to contribute to important research while providing better surveillance for their patients. We expect ASSURE to drive use of PancreaSure in new high-risk surveillance centers and increase testing volume among current customers. A further catalyst for growth is the extensive amount of new clinical data we expect to release in the second half of 2026. Compelling new data fosters regular, productive conversations with clinicians, which can drive test growth."
·11 t sittenThe risk of NE is, to say the least, imminent and will significantly affect trading until more is known. It's progressing and there's a chance for a partnership agreement, clearly. But time is short.
A decision on financing and a possible new share issue should be made absolutely no later than September. For the sake of credibility, we are talking about 80+MSEK, i.e., 1 year of financing (assuming then that sales increase quarter by quarter).- ·11 t sittenAI-assisted interpretation of annual report: They have already had preliminary contacts in Asia regarding PancreaSure. "Growing commercial traction and regulatory progress have stimulated preliminary discussions regarding commercial and strategic partnerships across the U.S., Japan, and China. Management highlights an accelerating industry-wide pace for licensing and acquisitions in cancer diagnostics."
This is the kind of thing one says when one has nothing to offer. Jeff has talked to someone for 2 minutes at a conference, and chooses to dedicate a paragraph in the report to it. Silly. Typical Jeff. Never anything of substance that one can scrutinize. Always vague promises about something that might come later. Either you have something to offer, or you wait. What do you mean "preliminary discussions"? What is your intention? What is your plan? What are you thinking with Asia? - ·11 t sitten · MuokattuAI-assisted reading of annual report: Slightly delayed Medicare submission.. Q3 now. Probably doesn't mean very much. Of course, a bit annoying. But are they hiring replacements for Lisa now? Regulatory & Clinical Catalysts Medicare Coverage Submission: Securing Medicare reimbursement remains a top strategic milestone. Immunovia remains on track to submit its coverage application in Q3 2026. The submission will be backed by pooled analysis data showing that PancreaSure detected 83.3% of Stage I and II cancers with 91.6% specificity in high-risk individuals presenting with signs or symptoms (matching Medicare target requirements). Clinical Studies & Real-World Evidence: The AFFIRM study results were published in the Journal of Clinical Oncology: Oncology Advances, highlighting strong late-stage detection and high specificity. Data collection for ADHERE (a survey measuring patient acceptance of an early-detection blood test) was completed in late Q2. The ASSURE registry study (a prospective, observational real-world study across 15–20 U.S. centers to evaluate clinical impact on physician decision-making) received ethics board approval and is actively contracting sites
- ·11 t sittenAI-assisted reading of annual report: Commercial Progress (PancreaSure) Center Adoption: Commercial momentum for PancreaSure accelerated in Q2 2026, with 6 new centers initiating testing, bringing the total to 27 high-risk surveillance centers using the test since its launch. Notably, 10 of the top 20 U.S. cancer hospitals have ordered PancreaSure tests. New additions in Q2 include prestigious institutions like Memorial Sloan Kettering, Endeavor Health, Providence Health, and Henry Ford Cancer Institute. Strategic Focus: The primary goal for the second half of 2026 is scaling testing volume and driving deeper test adoption within these already-onboarded accounts via the Strategic Account Manager team.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Tänään
‧40 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sitten · Muokattu".. the extensive amount of new clinical data we expect to release .." Found these positive lines from the report on the second half of 2026. When they release it, it can probably help the stock price a bit. Provided that everything goes as they hope: "A second catalyst will be the ASSURE registry, a real-world study of the PancreaSure test’s use and impact. The study has generated significant interest among pancreatic cancer experts, who see the study as a way to contribute to important research while providing better surveillance for their patients. We expect ASSURE to drive use of PancreaSure in new high-risk surveillance centers and increase testing volume among current customers. A further catalyst for growth is the extensive amount of new clinical data we expect to release in the second half of 2026. Compelling new data fosters regular, productive conversations with clinicians, which can drive test growth."
- ·11 t sittenThe risk of NE is, to say the least, imminent and will significantly affect trading until more is known. It's progressing and there's a chance for a partnership agreement, clearly. But time is short.A decision on financing and a possible new share issue should be made absolutely no later than September. For the sake of credibility, we are talking about 80+MSEK, i.e., 1 year of financing (assuming then that sales increase quarter by quarter).
- ·11 t sittenAI-assisted interpretation of annual report: They have already had preliminary contacts in Asia regarding PancreaSure. "Growing commercial traction and regulatory progress have stimulated preliminary discussions regarding commercial and strategic partnerships across the U.S., Japan, and China. Management highlights an accelerating industry-wide pace for licensing and acquisitions in cancer diagnostics."This is the kind of thing one says when one has nothing to offer. Jeff has talked to someone for 2 minutes at a conference, and chooses to dedicate a paragraph in the report to it. Silly. Typical Jeff. Never anything of substance that one can scrutinize. Always vague promises about something that might come later. Either you have something to offer, or you wait. What do you mean "preliminary discussions"? What is your intention? What is your plan? What are you thinking with Asia?
- ·11 t sitten · MuokattuAI-assisted reading of annual report: Slightly delayed Medicare submission.. Q3 now. Probably doesn't mean very much. Of course, a bit annoying. But are they hiring replacements for Lisa now? Regulatory & Clinical Catalysts Medicare Coverage Submission: Securing Medicare reimbursement remains a top strategic milestone. Immunovia remains on track to submit its coverage application in Q3 2026. The submission will be backed by pooled analysis data showing that PancreaSure detected 83.3% of Stage I and II cancers with 91.6% specificity in high-risk individuals presenting with signs or symptoms (matching Medicare target requirements). Clinical Studies & Real-World Evidence: The AFFIRM study results were published in the Journal of Clinical Oncology: Oncology Advances, highlighting strong late-stage detection and high specificity. Data collection for ADHERE (a survey measuring patient acceptance of an early-detection blood test) was completed in late Q2. The ASSURE registry study (a prospective, observational real-world study across 15–20 U.S. centers to evaluate clinical impact on physician decision-making) received ethics board approval and is actively contracting sites
- ·11 t sittenAI-assisted reading of annual report: Commercial Progress (PancreaSure) Center Adoption: Commercial momentum for PancreaSure accelerated in Q2 2026, with 6 new centers initiating testing, bringing the total to 27 high-risk surveillance centers using the test since its launch. Notably, 10 of the top 20 U.S. cancer hospitals have ordered PancreaSure tests. New additions in Q2 include prestigious institutions like Memorial Sloan Kettering, Endeavor Health, Providence Health, and Henry Ford Cancer Institute. Strategic Focus: The primary goal for the second half of 2026 is scaling testing volume and driving deeper test adoption within these already-onboarded accounts via the Strategic Account Manager team.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
2026 Q2 -tulosraportti
Tänään
‧40 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 5.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 6.8. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·10 t sitten · Muokattu".. the extensive amount of new clinical data we expect to release .." Found these positive lines from the report on the second half of 2026. When they release it, it can probably help the stock price a bit. Provided that everything goes as they hope: "A second catalyst will be the ASSURE registry, a real-world study of the PancreaSure test’s use and impact. The study has generated significant interest among pancreatic cancer experts, who see the study as a way to contribute to important research while providing better surveillance for their patients. We expect ASSURE to drive use of PancreaSure in new high-risk surveillance centers and increase testing volume among current customers. A further catalyst for growth is the extensive amount of new clinical data we expect to release in the second half of 2026. Compelling new data fosters regular, productive conversations with clinicians, which can drive test growth."
- ·11 t sittenThe risk of NE is, to say the least, imminent and will significantly affect trading until more is known. It's progressing and there's a chance for a partnership agreement, clearly. But time is short.A decision on financing and a possible new share issue should be made absolutely no later than September. For the sake of credibility, we are talking about 80+MSEK, i.e., 1 year of financing (assuming then that sales increase quarter by quarter).
- ·11 t sittenAI-assisted interpretation of annual report: They have already had preliminary contacts in Asia regarding PancreaSure. "Growing commercial traction and regulatory progress have stimulated preliminary discussions regarding commercial and strategic partnerships across the U.S., Japan, and China. Management highlights an accelerating industry-wide pace for licensing and acquisitions in cancer diagnostics."This is the kind of thing one says when one has nothing to offer. Jeff has talked to someone for 2 minutes at a conference, and chooses to dedicate a paragraph in the report to it. Silly. Typical Jeff. Never anything of substance that one can scrutinize. Always vague promises about something that might come later. Either you have something to offer, or you wait. What do you mean "preliminary discussions"? What is your intention? What is your plan? What are you thinking with Asia?
- ·11 t sitten · MuokattuAI-assisted reading of annual report: Slightly delayed Medicare submission.. Q3 now. Probably doesn't mean very much. Of course, a bit annoying. But are they hiring replacements for Lisa now? Regulatory & Clinical Catalysts Medicare Coverage Submission: Securing Medicare reimbursement remains a top strategic milestone. Immunovia remains on track to submit its coverage application in Q3 2026. The submission will be backed by pooled analysis data showing that PancreaSure detected 83.3% of Stage I and II cancers with 91.6% specificity in high-risk individuals presenting with signs or symptoms (matching Medicare target requirements). Clinical Studies & Real-World Evidence: The AFFIRM study results were published in the Journal of Clinical Oncology: Oncology Advances, highlighting strong late-stage detection and high specificity. Data collection for ADHERE (a survey measuring patient acceptance of an early-detection blood test) was completed in late Q2. The ASSURE registry study (a prospective, observational real-world study across 15–20 U.S. centers to evaluate clinical impact on physician decision-making) received ethics board approval and is actively contracting sites
- ·11 t sittenAI-assisted reading of annual report: Commercial Progress (PancreaSure) Center Adoption: Commercial momentum for PancreaSure accelerated in Q2 2026, with 6 new centers initiating testing, bringing the total to 27 high-risk surveillance centers using the test since its launch. Notably, 10 of the top 20 U.S. cancer hospitals have ordered PancreaSure tests. New additions in Q2 include prestigious institutions like Memorial Sloan Kettering, Endeavor Health, Providence Health, and Henry Ford Cancer Institute. Strategic Focus: The primary goal for the second half of 2026 is scaling testing volume and driving deeper test adoption within these already-onboarded accounts via the Strategic Account Manager team.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt